Comparison of high-dose, short-course levofloxacin treatment vs conventional regimen against acute bacterial infection: meta-analysis of randomized controlled trials

Figures & data

Table 1 Characteristics of included studies

Study, published year, ref.	Study design	Country	Study period	Study population	No. of patients		Dose regimen
					High-dose, short-course	Comparator	Levofloxacin	Comparator
Dunber et al, 2003^5	Multicenter, randomized, double-blind, active treatment-controlled	United States		Mild to severe CAP	256	272	Levofloxacin, 750 mg per day for 5 days	Levofloxacin, 500 mg per day for 10 days
Poole et al, 2006^11	Multicenter, randomized, open-label, controlled trial	United States		Acute sinusitis	389	391	Levofloxacin, 750 mg per day for 5 days	Levofloxacin, 500 mg per day for 10 days
Klausner et al, 2007^9	Multicenter, randomized, double-blind	United States	2005–2006	APN	146	165	Levofloxacin 750 mg per day for 5 days	Ciprofloxacin 400 mg IV or 500 mg oral, twice daily for 10 days
Peterson et al, 2008^10	Multicenter, double-blind, randomized study	United States		cUTI/APN	537	556	Levofloxacin 750 mg per day for 5 days	Ciprofloxacin 400 mg IV or 500 mg oral, twice daily for 10 days
Zhao et al, 2014^15	Multicenter, randomized, open-label, controlled trial	China	2007–2008	CAP	121	120	Levofloxacin, 750 mg per day for 5 days	Levofloxacin, 500 mg per day for 7–14 days
Zhao et al, 2016^14	Multicenter, randomized, open-label, controlled trial	China	2012–2014	CAP	221	227	Levofloxacin, 750 mg per day for 5 days	Levofloxacin, 500 mg per day for 7–14 days
Ren et al, 2017^12	Multicenter, randomized, open-label, controlled	China	2012–2014	cUTI/APN	165	165	Levofloxacin, 750 mg per day for 5 days	Levofloxacin, 500 mg per day for 7–14 days

Abbreviations: CAP, community-acquired pneumonia; APN, acute pylonephritis; cUTI, complicated urinary tract infection.

Figure 1 Flow diagram of the study selection process.

Figure 2 Summary of risk of biases.

Figure 3 Risk of bias per study and domain.ors

Figure 4 The overall clinical success between high-dose, short-course (HDSC) levofloxacin and conventional regimen in in the treatment of acute bacterial infections.

Figure 5 The overall microbiologic eradication rate between high-dose, short-course (HDSC) levofloxacin and conventional regimen in in the treatment of acute bacterial infections.

Figure 6 The risk of treatment-emergent adverse events between high-dose, short-course (HDSC) levofloxacin and conventional regimen in in the treatment of acute bacterial infections.